Expertise in
14
conditions

Dr. Gurkamal Chatta

Oncology
Bartlett Regional Hospital
3260 Hospital Dr, 
Juneau, AK 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Expertise in
14
conditions
Bartlett Regional Hospital
3260 Hospital Dr, 
Juneau, AK 

Overview

Gurkamal Chatta is an Oncologist practicing medicine in Juneau, Alaska.

Dr. Chatta is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Bladder Cancer, Urothelial Cancer, Prostatectomy, and Orchiectomy.

He is actively involved in clinical research, co-authoring 48 peer reviewed articles and participating in 12 clinical trials.

Specialties

Oncology

Licenses

Specialist in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Bartlett Regional Hospital
3260 Hospital Dr, Juneau, AK 99801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Nutrition and Exercise Interventions to Reduce Androgen Deprivation Therapy-Induced Obese Frailty in Survivors of Advanced Prostate Cancer
Nutrition and Exercise Interventions to Reduce Androgen Deprivation Therapy-Induced Obese Frailty in Survivors of Advanced Prostate Cancer
Enrollment Status: Recruiting
Publish Date: April 06, 2026
Intervention Type: Other, Dietary supplement, Behavioral
Study Phase: Not Applicable
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Enrollment Status: Recruiting
Publish Date: January 06, 2026
Intervention Type: Other
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Enrollment Status: Completed
Publish Date: February 04, 2026
Intervention Type: Genetic
Study Phase: Phase 1
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Completed
Publish Date: January 14, 2026
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
A Phase 1b Clinical Trial: Improving Outcomes With Androgen Pathway Inhibitors by Targeting DNA Methyltransferase Activity
A Phase 1b Clinical Trial: Improving Outcomes With Androgen Pathway Inhibitors by Targeting DNA Methyltransferase Activity
Enrollment Status: Terminated
Publish Date: November 12, 2025
Intervention Type: Drug
Study Drugs: Decitabine and Cedazuridine, Enzalutamide
Study Phase: Phase 1
Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen
Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2025
Intervention Type: Biological, Procedure, Drug
Study Drugs: Aspirin, Recombinant Interferon Alfa-2b, Rintatolimod
Study Phase: Phase 2
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Biological
Study Drugs: Enoblituzumab, Pembrolizumab, MGA012 Anti-PD-1 Antibody
Study Phase: Phase 1
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Procedure, Other, Biological, Drug
Study Drugs: Atezolizumab, Glycosylated Recombinant IL-7
Study Phase: Phase 2
Phase Ib/II Study of Enzalutamide With Venetoclax (ABT-199) in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Phase Ib/II Study of Enzalutamide With Venetoclax (ABT-199) in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drugs: Enzalutamide, Venetoclax
Study Phase: Phase 1
View 8 Less Clinical Trials

48 Total Publications

The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggests a window-of-opportunity for checkpoint inhibitor therapy in prostate cancer.
The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggests a window-of-opportunity for checkpoint inhibitor therapy in prostate cancer.
Journal: medRxiv : the preprint server for health sciences
Published: February 06, 2026
Similar Doctors
Expertise in
3
conditions
Dr. Paul Weiden
Oncology
Expertise in
3
conditions
Dr. Paul Weiden
Oncology

RBS Evolution Of Juneau LLC

1701 Salmon Creek Ln, 
Juneau, AK 
 (2568.5 miles away)
907-796-8720
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paul Weiden is an Oncologist practicing medicine in Juneau, Alaska. Dr. Weiden is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Paget Disease of the Breast, Breast Cancer, and Chronic B-Cell Leukemia (CBCL).

Frequently Asked Questions about Dr. Gurkamal Chatta

How do I make an appointment with Dr. Gurkamal Chatta?

You can book an appointment with Dr. Gurkamal Chatta by calling their office at 907-796-8920. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gurkamal Chatta a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gurkamal Chatta is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gurkamal Chatta specialize in?

While Dr. Gurkamal Chatta is a Oncology, they have specific expertise in Prostate Cancer, Bladder Cancer, and Urothelial Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Gurkamal Chatta participate in research or clinical trials?

Yes. Dr. Gurkamal Chatta has published 48 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Gurkamal Chatta's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gurkamal Chatta accept my insurance?

Dr. Gurkamal Chatta accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 907-796-8920 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chatta's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile